Strides Pharma buys four approved ANDAs from Nostrum Labs for over Rs 17 crore

Written by Ruchika Sharma Published On 2025-04-30T15:28:32+05:30 | Updated On 30 April 2025 3:28 PM IST

TPG to acquire 35% stake in SCHOTT Poonawalla from SII

Bengaluru: Strides Pharma Inc., a Step-down wholly-owned subsidiary of Strides Pharma Science Limited in the US, has acquired four approved Abbreviated New Drug Applications (ANDAs) from Nostrum Laboratories, Inc., USA., for more than Rs 17 crore for the US Market.

The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs (Urinary Tract Infections), Pain Management, Allergy Symptoms and Attention Deficit Disorder (ADD/ ADHD) and Narcolepsy.

The cumulative market size for the acquired portfolio is ~USD 57 million, as per IQVIA data of 2025.

Total consideration for acquisition of the said ANDAs is USD 2.075 million (~INR 176 million).

Read also: Strides Pharma Secures NCLT Approval for OneSource, India's First Specialty Pharma CDMO

"Two (out of the Four) ANDAs acquired are commercial products and is expected to be launched within 12 months. With access to these products, Strides will expand its portfolio of niche and difficult to manufacture products," the Company stated in a BSE filing.

Medical Dialogues team had earlier reported that Strides Pharma Global Pte. Limited (SPG), a step-down wholly-owned Subsidiary of the company in Singapore, had also entered into a Share Purchase Agreement to acquire 100 percent stake in Amexel for a nominal consideration of USD 10.

Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR). The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy and an institutional business to service donorfunded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company focuses on “difficult to manufacture” products sold in over 100 countries.

strides pharmaacquisitionstrides pharma sciencenostrum labsurinary tract infectionsallergyattention deficit disordernarcolepsy

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751